argenx SE (NASDAQ:ARGX) Shares Bought by Van ECK Associates Corp

Van ECK Associates Corp raised its stake in argenx SE (NASDAQ:ARGX) by 22.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 46,809 shares of the company’s stock after purchasing an additional 8,568 shares during the quarter. Van ECK Associates Corp’s holdings in argenx were worth $28,788,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC boosted its holdings in shares of argenx by 38,152.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company’s stock valued at $89,391,000 after purchasing an additional 143,834 shares during the last quarter. Marks Group Wealth Management Inc boosted its holdings in shares of argenx by 11.7% in the 4th quarter. Marks Group Wealth Management Inc now owns 1,316 shares of the company’s stock valued at $809,000 after purchasing an additional 138 shares during the last quarter. Stephens Inc. AR acquired a new position in shares of argenx during the 4th quarter valued at $310,000. Wilmington Savings Fund Society FSB lifted its holdings in shares of argenx by 47.8% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 1,776 shares of the company’s stock valued at $1,092,000 after acquiring an additional 574 shares in the last quarter. Finally, Advisors Preferred LLC acquired a new position in shares of argenx during the 4th quarter valued at $73,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Stock Performance

ARGX opened at $639.41 on Friday. The company has a 50-day moving average of $639.59 and a 200-day moving average of $581.81. The company has a market capitalization of $38.85 billion, a P/E ratio of -726.60 and a beta of 0.58. argenx SE has a 1-year low of $349.86 and a 1-year high of $678.21.

Analyst Upgrades and Downgrades

ARGX has been the topic of several recent research reports. Robert W. Baird lowered shares of argenx from an “outperform” rating to a “neutral” rating and lifted their target price for the company from $515.00 to $650.00 in a report on Friday, November 1st. William Blair upgraded shares of argenx from a “market perform” rating to an “outperform” rating in a report on Friday, November 1st. Truist Financial restated a “buy” rating and set a $700.00 target price (up previously from $660.00) on shares of argenx in a report on Tuesday, January 14th. Piper Sandler lifted their target price on shares of argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a report on Tuesday, January 7th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of argenx from a “hold” rating to a “sell” rating in a report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $658.39.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.